Frontiers in Immunology (Feb 2024)

Identification and validation of UBE2B as a prognostic biomarker promoting the development of esophageal carcinomas

  • Han Ding,
  • Han Ding,
  • Jia-Cheng Xu,
  • Zhi-Guo Ding,
  • Lin-Feng Wu,
  • Lin-Feng Wu,
  • Yan-Bo Liu,
  • Yan-Bo Liu,
  • Yi-Fei Zhang,
  • Yi-Fei Zhang,
  • Tian-Yin Chen,
  • Tian-Yin Chen,
  • Yi-Qun Zhang,
  • Yi-Qun Zhang,
  • Ping-Hong Zhou,
  • Ping-Hong Zhou

DOI
https://doi.org/10.3389/fimmu.2024.1295305
Journal volume & issue
Vol. 15

Abstract

Read online

IntroductionUbiquitination is a crucial biological mechanism in humans, essential for regulating vital biological processes, and has been recognized as a promising focus for cancer therapy. Our objective in this research was to discover potential enzymes associated with ubiquitination that may serve as therapeutic targets for individuals with esophageal carcinoma (ESCA).MethodsTo identify genes linked to the prognosis of ESCA, we examined mRNA sequencing data from patients with ESCA in the TCGA database. Further investigation into the role of the candidate gene in ESCA was conducted through bioinformatic analyses. Subsequently, we carried out biological assays to assess its impact on ESCA development.ResultsThrough univariate Cox regression analysis, we identified Ubiquitin Conjugating Enzyme E2 B (UBE2B) as a potential gene associated with the prognosis of ESCA. UBE2B exhibited significant upregulation and was found to be correlated with survival outcomes in ESCA as well as other cancer types. Additionally, UBE2B was observed to be involved in various biological pathways linked to the development of ESCA, including TNF-a signaling via NF-κB, epithelial-mesenchymal transition, inflammatory response, and hypoxia. Moreover, immune-related pathways like B cell activation (GO: 0042113), B cell receptor signaling pathway (GO: 0050853) and B cell mediated immunity (GO:0019724) were also involved. It was found that high expression of UBE2B was correlated with the increase of several kinds of T cells (CD8 T cells, Th1 cells) and macrophages, while effector memory T cell (Tem) and Th17 cells decreased. Furthermore, UBE2B showed potential as a prognostic biomarker for ESCA, displaying high sensitivity and specificity. Notably, proliferation and migration in ESCA cells were effectively suppressed when the expression of UBE2B was knocked down.ConclusionsTo summarize, this study has made a discovery regarding the importance of gaining new insights into the role of UBE2B in ESCA. UBE2B might be an oncogene with good ability in predicting and diagnosing ESCA. Consequently, this discovery highlights the feasibility of targeting UBE2B as a viable approach for treating patients with ESCA.

Keywords